International Journal of Translational Medicine (Nov 2021)

Nanomedicine for Treating Diabetic Retinopathy Vascular Degeneration

  • Tatiana Borodina,
  • Dmitry Kostyushev,
  • Andrey A. Zamyatnin,
  • Alessandro Parodi

DOI
https://doi.org/10.3390/ijtm1030018
Journal volume & issue
Vol. 1, no. 3
pp. 306 – 322

Abstract

Read online

The incidence of diabetes and the pathological conditions associated with chronic hyperglycemia is increasing worldwide. Among them, diabetic retinopathy represents a leading cause of vision loss, causing a significant structural and functional impairment of the retinal and choroidal capillary network. Current therapies include anti-angiogenic and anti-inflammatory drugs administered through repetitive and invasive intraocular injections, and associated with significant adverse effects. The presence of ocular barriers affects the efficiency of topically administered therapeutics for treating the posterior segment of the eye. In this scenario, nanomedicine could improve current therapies for diabetic retinopathy by providing tools that can decrease the number of injections thanks to their controlled release properties, while some materials showed a natural ability to mitigate pathological neo-angiogenesis. Moreover, specific surface modifications could open new scenarios for the development of topical treatments. This review describes current advances in generating nanomedicine for diabetic retinopathy, focusing on the properties of the different materials tested explicitly for this purpose.

Keywords